Literature DB >> 16026644

Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma.

Tamer E Fandy1, Sharmila Shankar, Douglas D Ross, Edward Sausville, Rakesh K Srivastava.   

Abstract

In this study, we have evaluated the cytotoxic effect of combining two HDAC inhibitors, SAHA and TSA, with TRAIL in human multiple myeloma cell lines. Low doses of SAHA or TSA enhanced the cytotoxic and apoptotic effects of TRAIL and upregulated the surface expression of TRAIL death receptors (DR4 and/or DR5). SAHA and TSA induced G1 phase cell cycle growth arrest by upregulating p21(WAF1) and p27(Kip1) expression and by inhibiting E2F transcriptional activity. The enhanced TRAIL effect after pretreatment with HDAC inhibitors was consistent with the upregulation of the proapoptotic Bcl-2 family members (Bim, Bak, Bax, Noxa, and PUMA), the downregulation of the anti-apoptotic members of the Bcl-2 family (Bcl-2 and Bcl-X(L)), and IAPs. SAHA and TSA dissipated the mitochondrial membrane potential and enhanced the release of Omi/HtrA2 and AIF from the mitochondria to the cytosol. The cytotoxic effect of both SAHA and TSA was caspase- and calpain-independent. Inhibition of NF(kappa)B activation by the proteasome inhibitor, MG132, enhanced the apoptotic effect of TSA. Our study demonstrated the enhancing effects of HDAC inhibitors on apoptosis when combined with TRAIL and, for the first time, emphasized the role of AIF in mediating the cytotoxic effects of HDAC inhibitors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16026644      PMCID: PMC1501425          DOI: 10.1593/neo.04655

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  63 in total

1.  E2F3 activity is regulated during the cell cycle and is required for the induction of S phase.

Authors:  G Leone; J DeGregori; Z Yan; L Jakoi; S Ishida; R S Williams; J R Nevins
Journal:  Genes Dev       Date:  1998-07-15       Impact factor: 11.361

2.  Molecular characterization of mitochondrial apoptosis-inducing factor.

Authors:  S A Susin; H K Lorenzo; N Zamzami; I Marzo; B E Snow; G M Brothers; J Mangion; E Jacotot; P Costantini; M Loeffler; N Larochette; D R Goodlett; R Aebersold; D P Siderovski; J M Penninger; G Kroemer
Journal:  Nature       Date:  1999-02-04       Impact factor: 49.962

3.  Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.

Authors:  F Facchetti; S Previdi; M Ballarini; S Minucci; P Perego; C A M La Porta
Journal:  Apoptosis       Date:  2004-09       Impact factor: 4.677

4.  In the erythroleukemic cell line HEL Prostate-apoptosis-response-gene-4 (par-4) fails to down-regulate Bcl-2 and to promote apoptosis.

Authors:  Simone Boehrer; Angela Brieger; Simone Schaaf; Natasa Kukoc-Zivojnov; Daniel Nowak; Martin Ruthardt; Dieter Hoelzer; Paris S Mitrou; Eckhart Weidmann; Kai Uwe Chow
Journal:  Leuk Lymphoma       Date:  2004-07

5.  Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect.

Authors:  Pavan Reddy; Yoshinobu Maeda; Kevin Hotary; Chen Liu; Leonid L Reznikov; Charles A Dinarello; James L M Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-04       Impact factor: 11.205

6.  Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1).

Authors:  V Chopin; C Slomianny; H Hondermarck; X Le Bourhis
Journal:  Exp Cell Res       Date:  2004-08-15       Impact factor: 3.905

7.  Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells.

Authors:  Susumu Nakata; Tatsushi Yoshida; Mano Horinaka; Takumi Shiraishi; Miki Wakada; Toshiyuki Sakai
Journal:  Oncogene       Date:  2004-08-19       Impact factor: 9.867

8.  Contribution of disruption of the nuclear factor-kappaB pathway to induction of apoptosis in human leukemia cells by histone deacetylase inhibitors and flavopiridol.

Authors:  Ning Gao; Yun Dai; Mohamed Rahmani; Paul Dent; Steven Grant
Journal:  Mol Pharmacol       Date:  2004-07-02       Impact factor: 4.436

9.  Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells.

Authors:  Patrick S Moore; Stefano Barbi; Massimo Donadelli; Chiara Costanzo; Claudio Bassi; Marta Palmieri; Aldo Scarpa
Journal:  Biochim Biophys Acta       Date:  2004-09-17

Review 10.  Epigenetics in human disease and prospects for epigenetic therapy.

Authors:  Gerda Egger; Gangning Liang; Ana Aparicio; Peter A Jones
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

View more
  50 in total

1.  Inhibition of matrine against gastric cancer cell line MNK45 growth and its anti-tumor mechanism.

Authors:  Cong Luo; Hai Jun Zhong; Li Ming Zhu; Xian Guo Wu; Jie Er Ying; Xiao Hong Wang; Wang Xia Lü; Qi Xu; Yong Liang Zhu; Jian Huang
Journal:  Mol Biol Rep       Date:  2011-12-30       Impact factor: 2.316

2.  Early prediction of response to Vorinostat in an orthotopic rat glioma model.

Authors:  Li Wei; Samuel Hong; Younghyoun Yoon; Scott N Hwang; Jaekeun C Park; Zhaobin Zhang; Jeffrey J Olson; Xiaoping P Hu; Hyunsuk Shim
Journal:  NMR Biomed       Date:  2012-02-02       Impact factor: 4.044

Review 3.  Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat.

Authors:  Salma Afifi; Angela Michael; Mahshid Azimi; Mabel Rodriguez; Nikoletta Lendvai; Ola Landgren
Journal:  Pharmacotherapy       Date:  2015-12       Impact factor: 4.705

Review 4.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

5.  Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death.

Authors:  Sanjib Chowdhury; Gillian M Howell; Carol A Teggart; Aparajita Chowdhury; Jonathan J Person; Dawn M Bowers; Michael G Brattain
Journal:  J Biol Chem       Date:  2011-07-08       Impact factor: 5.157

Review 6.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

7.  Histone deacetylase inhibitors in the treatment for multiple myeloma.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Int J Hematol       Date:  2013-03-10       Impact factor: 2.490

8.  HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.

Authors:  Choon-Kee Lee; Shuiliang Wang; Xiaoping Huang; John Ryder; Bolin Liu
Journal:  Cancer Lett       Date:  2010-05-05       Impact factor: 8.679

Review 9.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

10.  Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.

Authors:  S R Green; A K Choudhary; I N Fleming
Journal:  Br J Cancer       Date:  2010-10-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.